Please enable JavaScript to continue using this application.

Compare $SPRB vs $VTVT | Chartloom

Compare

$SPRB vs $VTVT

Spruce Biosciences, Inc · vTv Therapeutics Inc

SPRB

Spruce Biosciences, Inc

VTVT

vTv Therapeutics Inc

Compare $SPRB vs $VTVT

Comparing Spruce Biosciences, Inc and vTv Therapeutics Inc

SPRBSpruce Biosciences, Inc

VTVTvTv Therapeutics Inc

SPRBSpruce Biosciences, Inc

Market cap

$121M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-51.4%

52W performance

-72.5%

FCF yield

-35.3%

VTVTvTv Therapeutics Inc

Market cap

$123M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

216600.0%

YTD performance

-21.3%

52W performance

38.3%

FCF yield

-13.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

SPRB

VTVT

Detailed metrics comparison

SPRB

Spruce Biosciences, Inc

VTVT

vTv Therapeutics Inc

Market Cap

SPRB$121M

VTVT$123M

Enterprise Value

SPRB$32M

VTVT$36M

Price

SPRB$44.05

VTVT$31.18

P/E Ratio

SPRBN/A

VTVTN/A

P/S Ratio

SPRB26.75x

VTVT3.33x

EV/Sales

SPRB8.59x

VTVT0.98x

EV/EBITDA

SPRB0.00x

VTVT0.00x

P/B Ratio

SPRB1.57x

VTVT1.53x

P/FCF Ratio

SPRBN/A

VTVTN/A

EV/FCF

SPRB-0.75x

VTVT-2.16x

PEG Ratio

SPRBN/A

VTVTN/A

Forward P/E (NTM)

SPRBN/A

VTVTN/A

Forward P/S (NTM)

SPRBN/A

VTVTN/A

Revenue (TTM)

SPRB$0

VTVT$37M

Revenue Growth (YoY)

SPRBN/A

VTVT216600.0%

Forward Rev Growth

SPRB-75.6%

VTVT-97.3%

Gross Margin (TTM)

SPRB0.0%

VTVT0.0%

Operating Margin (TTM)

SPRB0.0%

VTVT63.1%

EBITDA Margin (TTM)

SPRB0.0%

VTVT-25.1%

Net Margin (TTM)

SPRB0.0%

VTVT-12.9%

FCF Margin (TTM)

SPRBN/A

VTVT-45.5%

Net Income (TTM)

SPRB$-51M

VTVT$-5M

FCF (TTM)

SPRB$-43M

VTVT$-17M

EPS (TTM)

SPRB-$21.14

VTVT-$0.38

ROE (TTM)

SPRB-15540.0%

VTVT-627.0%

ROA (TTM)

SPRB-10167.0%

VTVT-506.0%

ROIC (TTM)

SPRB-14349.0%

VTVT-626.0%

Cash

SPRB$96M

VTVT$87M

Debt

SPRB$7M

VTVT$0

Net Cash/Debt

SPRB$89M

VTVT$87M

Current Ratio (TTM)

SPRB9.23x

VTVT12.48x

Quick Ratio (TTM)

SPRB8.81x

VTVT12.42x

Debt/Equity (TTM)

SPRB0.08x

VTVT0.00x

Debt/Assets (TTM)

SPRB0.0%

VTVT0.0%

Interest Coverage (TTM)

SPRBN/A

VTVTN/A

Net Debt/EBITDA (TTM)

SPRB0.00x

VTVT0.00x

Beta

SPRB3.63

VTVT0.23

52W Performance

SPRB-72.5%

VTVT38.3%

YTD Performance

SPRB-51.4%

VTVT-21.3%

% from 52W High

SPRB-77.9%

VTVT-29.1%

% from 52W Low

SPRB9.2%

VTVT59.9%

Asset Turnover (TTM)

SPRB0.07x

VTVT0.37x

FCF Yield (TTM)

SPRB-35.3%

VTVT-13.6%

Earnings Yield (TTM)

SPRB-42.4%

VTVT-3.9%

Dividend Yield (TTM)

SPRBN/A

VTVTN/A

Rule of 40

SPRB0.0

VTVT216,554.5

EV/GP/RG

SPRBN/A

VTVTN/A

Ticker research

View SPRB research View VTVT research

Metric	SPRB Spruce Biosciences, Inc	VTVT vTv Therapeutics Inc
Market & Valuation
Market Cap	$121M	$123M
Enterprise Value	$32M	$36M
Price	$44.05	$31.18
P/E Ratio	N/A	N/A
P/S Ratio	26.75x	3.33x
EV/Sales	8.59x	0.98x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.57x	1.53x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.75x	-2.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$37M
Revenue Growth (YoY)	N/A	216600.0%
Forward Rev Growth	-75.6%	-97.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	63.1%
EBITDA Margin (TTM)	0.0%	-25.1%
Net Margin (TTM)	0.0%	-12.9%
FCF Margin (TTM)	N/A	-45.5%
Net Income (TTM)	$-51M	$-5M
FCF (TTM)	$-43M	$-17M
EPS (TTM)	-$21.14	-$0.38
ROE (TTM)	-15540.0%	-627.0%
ROA (TTM)	-10167.0%	-506.0%
ROIC (TTM)	-14349.0%	-626.0%
Financial Health
Cash	$96M	$87M
Debt	$7M	$0
Net Cash/Debt	$89M	$87M
Current Ratio (TTM)	9.23x	12.48x
Quick Ratio (TTM)	8.81x	12.42x
Debt/Equity (TTM)	0.08x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.63	0.23
52W Performance	-72.5%	38.3%
YTD Performance	-51.4%	-21.3%
% from 52W High	-77.9%	-29.1%
% from 52W Low	9.2%	59.9%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.37x
FCF Yield (TTM)	-35.3%	-13.6%
Earnings Yield (TTM)	-42.4%	-3.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	216,554.5
EV/GP/RG	N/A	N/A
Ticker research	View SPRB research	View VTVT research

Valuation

P/S Ratio

VTVT

3.33x

SPRB

26.75x

EV/FCF

VTVT

-2.16x

SPRB

-0.75x

Growth & revenue

Revenue Growth TTM

VTVT

216600.0%

Forward Revenue Growth

SPRB

-75.6%

VTVT

-97.3%

Profitability & performance

Gross Margin

SPRB

0.0%

VTVT

0.0%

ROE

VTVT

-627.0%

SPRB

-15540.0%

FCF Yield %

VTVT

-13.6%

SPRB

-35.3%

52-Week Performance

VTVT

38.3%

SPRB

-72.5%

Detailed metrics comparison

SPRB

Spruce Biosciences, Inc

VTVT

vTv Therapeutics Inc

Market Cap

SPRB$121M

VTVT$123M

Enterprise Value

SPRB$32M

VTVT$36M

Price

SPRB$44.05

VTVT$31.18

P/E Ratio

SPRBN/A

VTVTN/A

P/S Ratio

SPRB26.75x

VTVT3.33x

EV/Sales

SPRB8.59x

VTVT0.98x

EV/EBITDA

SPRB0.00x

VTVT0.00x

P/B Ratio

SPRB1.57x

VTVT1.53x

P/FCF Ratio

SPRBN/A

VTVTN/A

EV/FCF

SPRB-0.75x

VTVT-2.16x

PEG Ratio

SPRBN/A

VTVTN/A

Forward P/E (NTM)

SPRBN/A

VTVTN/A

Forward P/S (NTM)

SPRBN/A

VTVTN/A

Revenue (TTM)

SPRB$0

VTVT$37M

Revenue Growth (YoY)

SPRBN/A

VTVT216600.0%

Forward Rev Growth

SPRB-75.6%

VTVT-97.3%

Gross Margin (TTM)

SPRB0.0%

VTVT0.0%

Operating Margin (TTM)

SPRB0.0%

VTVT63.1%

EBITDA Margin (TTM)

SPRB0.0%

VTVT-25.1%

Net Margin (TTM)

SPRB0.0%

VTVT-12.9%

FCF Margin (TTM)

SPRBN/A

VTVT-45.5%

Net Income (TTM)

SPRB$-51M

VTVT$-5M

FCF (TTM)

SPRB$-43M

VTVT$-17M

EPS (TTM)

SPRB-$21.14

VTVT-$0.38

ROE (TTM)

SPRB-15540.0%

VTVT-627.0%

ROA (TTM)

SPRB-10167.0%

VTVT-506.0%

ROIC (TTM)

SPRB-14349.0%

VTVT-626.0%

Cash

SPRB$96M

VTVT$87M

Debt

SPRB$7M

VTVT$0

Net Cash/Debt

SPRB$89M

VTVT$87M

Current Ratio (TTM)

SPRB9.23x

VTVT12.48x

Quick Ratio (TTM)

SPRB8.81x

VTVT12.42x

Debt/Equity (TTM)

SPRB0.08x

VTVT0.00x

Debt/Assets (TTM)

SPRB0.0%

VTVT0.0%

Interest Coverage (TTM)

SPRBN/A

VTVTN/A

Net Debt/EBITDA (TTM)

SPRB0.00x

VTVT0.00x

Beta

SPRB3.63

VTVT0.23

52W Performance

SPRB-72.5%

VTVT38.3%

YTD Performance

SPRB-51.4%

VTVT-21.3%

% from 52W High

SPRB-77.9%

VTVT-29.1%

% from 52W Low

SPRB9.2%

VTVT59.9%

Asset Turnover (TTM)

SPRB0.07x

VTVT0.37x

FCF Yield (TTM)

SPRB-35.3%

VTVT-13.6%

Earnings Yield (TTM)

SPRB-42.4%

VTVT-3.9%

Dividend Yield (TTM)

SPRBN/A

VTVTN/A

Rule of 40

SPRB0.0

VTVT216,554.5

EV/GP/RG

SPRBN/A

VTVTN/A

Ticker research

View SPRB research View VTVT research

Metric	SPRB Spruce Biosciences, Inc	VTVT vTv Therapeutics Inc
Market & Valuation
Market Cap	$121M	$123M
Enterprise Value	$32M	$36M
Price	$44.05	$31.18
P/E Ratio	N/A	N/A
P/S Ratio	26.75x	3.33x
EV/Sales	8.59x	0.98x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.57x	1.53x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.75x	-2.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$37M
Revenue Growth (YoY)	N/A	216600.0%
Forward Rev Growth	-75.6%	-97.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	63.1%
EBITDA Margin (TTM)	0.0%	-25.1%
Net Margin (TTM)	0.0%	-12.9%
FCF Margin (TTM)	N/A	-45.5%
Net Income (TTM)	$-51M	$-5M
FCF (TTM)	$-43M	$-17M
EPS (TTM)	-$21.14	-$0.38
ROE (TTM)	-15540.0%	-627.0%
ROA (TTM)	-10167.0%	-506.0%
ROIC (TTM)	-14349.0%	-626.0%
Financial Health
Cash	$96M	$87M
Debt	$7M	$0
Net Cash/Debt	$89M	$87M
Current Ratio (TTM)	9.23x	12.48x
Quick Ratio (TTM)	8.81x	12.42x
Debt/Equity (TTM)	0.08x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.63	0.23
52W Performance	-72.5%	38.3%
YTD Performance	-51.4%	-21.3%
% from 52W High	-77.9%	-29.1%
% from 52W Low	9.2%	59.9%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.37x
FCF Yield (TTM)	-35.3%	-13.6%
Earnings Yield (TTM)	-42.4%	-3.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	216,554.5
EV/GP/RG	N/A	N/A
Ticker research	View SPRB research	View VTVT research